IN.PACT SFA Trial Update: Presented by Peter Schneider, M.D at Vascular Interventional Advances (VIVA) 2017 conference in Las Vegas).

IN.PACT SFA enrolled 331 patients with symptomatic femoropopliteal lesions.  Four-year results of the IN.PACT SFA trial demonstrated sustained treatment effect in maintaining significantly higher freedom from CD-TLR by KM estimate in patients treated with the In.Pact Admiral DCB compared to PTA despite a late catch-up effect. Among patients requiring reintervention, the mean time to the first event was significantly longer in the DCB group.